Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 2/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.47 |
| ▸ | ESR1 | P03372 | 9/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 9/20 | 0.47 |
| ▸ | AR | P10275 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 4/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23205942 | 0.82 | ALOX5AP (0.45) | CYP11B1CYP11B2KDM4EALDH1A1HPGD | |
| SCHEMBL12988126 | 0.79 | CYP11B1 (0.52) | CYP11B1CYP11B2ESR1ESR2KDM4E | |
| SCHEMBL15419971 | 0.79 | AR (0.47) | CYP11B1CYP11B2ESR1ESR2AR | |
| SCHEMBL2786052 | 0.79 | KIF11 (0.59) | CYP11B1CYP11B2ESR1ESR2AR | |
| SCHEMBL9063141 | 0.79 | KIF11 (0.59) | CYP11B1CYP11B2ESR1ESR2AR | |
| SCHEMBL15420520 | 0.78 | ALDH1A1 (0.47) | CYP11B1CYP11B2KDM4EALDH1A1HPGD | |
| SCHEMBL9021665 | 0.78 | KDM4E (0.61) | CYP11B1CYP11B2KDM4EALDH1A1HPGD | |
| SCHEMBL2433081 | 0.77 | MMP3 (0.59) | CYP11B1ESR1ESR2KDM4EALDH1A1 | |
| SCHEMBL10355365 | 0.77 | KDM4E (0.54) | CYP11B1CYP11B2KDM4EALDH1A1HPGD | |
| SCHEMBL12987472 | 0.76 | CYP11B1 (0.50) | CYP11B1CYP11B2ESR1ESR2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2694472-B1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2020-03-11 | — | — | EP | disclosed |
| US-9527807-B2 | Sulfonamide derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-12-27 | — | — | US | disclosed |
| US-20140024650-A1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140024650-A1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | GRIN2A, GRIN2B, SLC1A2 | CYP11B1 1565/4885CYP11B2 1213/4885ESR1 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.